Incremental Healthcare Costs and Outpatient Antifungal Treatment of Patients with Aspergillosis in the United States
**Objectives:** To evaluate the total and outpatient economic burden of aspergillosis, and to describe the outpatient antifungal treatment of aspergillosis within a large, commercially-insured population in the United States. **Methods:** Adults with at least one medical claim with an aspergillosis...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Columbia Data Analytics, LLC
2013-10-01
|
| Series: | Journal of Health Economics and Outcomes Research |
| Online Access: | https://doi.org/10.36469/9862 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1823860369404198912 |
|---|---|
| author | Emily Durden Donna McMorrow Paul Juneau Robert Fowler Paresh Chaudhari David Horn |
| author_facet | Emily Durden Donna McMorrow Paul Juneau Robert Fowler Paresh Chaudhari David Horn |
| author_sort | Emily Durden |
| collection | DOAJ |
| description | **Objectives:** To evaluate the total and outpatient economic burden of aspergillosis, and to describe the outpatient antifungal treatment of aspergillosis within a large, commercially-insured population in the United States.
**Methods:** Adults with at least one medical claim with an aspergillosis diagnosis (International Classification of Disease 9th Revision Clinical Modification [ICD-9-CM] code 117.3 or 484.6) between 07/01/04-03/01/11 were identified from the MarketScan Research Databases. Patients had ≥6 months of pre-index and ≥1 month of post-index continuous health plan and pharmacy benefit enrollment and no pre-index diagnosis of aspergillosis. Aspergillosis cases were propensity score-matched to a sample of controls without aspergillosis. Outpatient antifungal therapy and total and outpatient healthcare resource utilization were evaluated in the post-index period. General linear models were used to estimate costs, which were adjusted by the length of follow-up. Incremental costs were calculated between cohorts and a bootstrap procedure was used to produce corresponding variation and 95% confidence interval estimates.
**Results:** Aspergillosis cases (N=5,499; mean age: 57.8 years; 48.6% female; 64.2% with cancer) were matched to 5,499 controls (mean age: 58.3 years; 48.4% female; 60.6% with cancer). Two-thirds of the aspergillosis cases had no outpatient prescription for an antifungal within 30 days of index; for those with outpatient antifungal therapy, voriconazole was the most commonly prescribed agent (60.9%). Average adjusted total and outpatient expenditures were greater for aspergillosis patients during follow-up than those of the matched controls ($26,680 and $9,248 greater, respectively).
**Conclusions:** The economic burden of aspergillosis is substantial. Patients with aspergillosis utilize significantly more healthcare resources and thus incur greater healthcare costs than do similar patients without aspergillosis. |
| format | Article |
| id | doaj-art-b72248b833a54b9cb1bbf12087f020e5 |
| institution | Kabale University |
| issn | 2327-2236 |
| language | English |
| publishDate | 2013-10-01 |
| publisher | Columbia Data Analytics, LLC |
| record_format | Article |
| series | Journal of Health Economics and Outcomes Research |
| spelling | doaj-art-b72248b833a54b9cb1bbf12087f020e52025-02-10T16:12:29ZengColumbia Data Analytics, LLCJournal of Health Economics and Outcomes Research2327-22362013-10-0112Incremental Healthcare Costs and Outpatient Antifungal Treatment of Patients with Aspergillosis in the United StatesEmily DurdenDonna McMorrowPaul JuneauRobert FowlerParesh ChaudhariDavid Horn**Objectives:** To evaluate the total and outpatient economic burden of aspergillosis, and to describe the outpatient antifungal treatment of aspergillosis within a large, commercially-insured population in the United States. **Methods:** Adults with at least one medical claim with an aspergillosis diagnosis (International Classification of Disease 9th Revision Clinical Modification [ICD-9-CM] code 117.3 or 484.6) between 07/01/04-03/01/11 were identified from the MarketScan Research Databases. Patients had ≥6 months of pre-index and ≥1 month of post-index continuous health plan and pharmacy benefit enrollment and no pre-index diagnosis of aspergillosis. Aspergillosis cases were propensity score-matched to a sample of controls without aspergillosis. Outpatient antifungal therapy and total and outpatient healthcare resource utilization were evaluated in the post-index period. General linear models were used to estimate costs, which were adjusted by the length of follow-up. Incremental costs were calculated between cohorts and a bootstrap procedure was used to produce corresponding variation and 95% confidence interval estimates. **Results:** Aspergillosis cases (N=5,499; mean age: 57.8 years; 48.6% female; 64.2% with cancer) were matched to 5,499 controls (mean age: 58.3 years; 48.4% female; 60.6% with cancer). Two-thirds of the aspergillosis cases had no outpatient prescription for an antifungal within 30 days of index; for those with outpatient antifungal therapy, voriconazole was the most commonly prescribed agent (60.9%). Average adjusted total and outpatient expenditures were greater for aspergillosis patients during follow-up than those of the matched controls ($26,680 and $9,248 greater, respectively). **Conclusions:** The economic burden of aspergillosis is substantial. Patients with aspergillosis utilize significantly more healthcare resources and thus incur greater healthcare costs than do similar patients without aspergillosis.https://doi.org/10.36469/9862 |
| spellingShingle | Emily Durden Donna McMorrow Paul Juneau Robert Fowler Paresh Chaudhari David Horn Incremental Healthcare Costs and Outpatient Antifungal Treatment of Patients with Aspergillosis in the United States Journal of Health Economics and Outcomes Research |
| title | Incremental Healthcare Costs and Outpatient Antifungal Treatment of Patients with Aspergillosis in the United States |
| title_full | Incremental Healthcare Costs and Outpatient Antifungal Treatment of Patients with Aspergillosis in the United States |
| title_fullStr | Incremental Healthcare Costs and Outpatient Antifungal Treatment of Patients with Aspergillosis in the United States |
| title_full_unstemmed | Incremental Healthcare Costs and Outpatient Antifungal Treatment of Patients with Aspergillosis in the United States |
| title_short | Incremental Healthcare Costs and Outpatient Antifungal Treatment of Patients with Aspergillosis in the United States |
| title_sort | incremental healthcare costs and outpatient antifungal treatment of patients with aspergillosis in the united states |
| url | https://doi.org/10.36469/9862 |
| work_keys_str_mv | AT emilydurden incrementalhealthcarecostsandoutpatientantifungaltreatmentofpatientswithaspergillosisintheunitedstates AT donnamcmorrow incrementalhealthcarecostsandoutpatientantifungaltreatmentofpatientswithaspergillosisintheunitedstates AT pauljuneau incrementalhealthcarecostsandoutpatientantifungaltreatmentofpatientswithaspergillosisintheunitedstates AT robertfowler incrementalhealthcarecostsandoutpatientantifungaltreatmentofpatientswithaspergillosisintheunitedstates AT pareshchaudhari incrementalhealthcarecostsandoutpatientantifungaltreatmentofpatientswithaspergillosisintheunitedstates AT davidhorn incrementalhealthcarecostsandoutpatientantifungaltreatmentofpatientswithaspergillosisintheunitedstates |